Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Nucor Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Nucor Corporation trades at $227.37 (market cap $51.78B). The key difference: Nucor Corporation is the larger of the two by market cap, and Nucor Corporation pays a 0.99% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NUE | |
|---|---|---|
Market Cap | $39.89B | $51.78B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $266.35 |
52-Week Low | $278.09 | $131.78 |
Enterprise Value | $38.15B | $56.42B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Nucor (NUE) trades at $227.37, up 2.29% today, with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 22.56 and net margin of 6.82%, while revenue has declined from $41.5B in 2022 to $32.5B in 2025. Recent news highlights a joint venture for AI power infrastructure and a 53-year dividend growth streak, supporting shareholder returns amid steel price volatility.
Outlook remains cautiously optimistic with a consensus price target of $262.89 (15.6% upside), driven by expansion projects and pricing strength. Risks include cyclical demand weakness and declining operating cash flow, but analyst sentiment is 59% buy-rated. The stock offers value through dividends and buybacks, though investors should monitor steel market dynamics and execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
